Published in

Wiley Open Access, Influenza and Other Respiratory Viruses, 5(17), 2023

DOI: 10.1111/irv.13150

Links

Tools

Export citation

Search in Google Scholar

Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England

Journal article published in 2023 by Katie Harman ORCID, Sophie Grace Nash ORCID, Harriet H. Webster ORCID, Natalie Groves ORCID, Jo Hardstaff ORCID, Jessica Bridgen ORCID, Paula B. Blomquist ORCID, Russell Hope ORCID, Efejiro Ashano ORCID, Richard Myers ORCID, Sakib Rokadiya ORCID, Susan Hopkins ORCID, Colin S. Brown ORCID, Meera Chand ORCID, Gavin Dabrera ORCID and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

AbstractThere are concerns that sotrovimab has reduced efficacy at reducing hospitalisation risk against the BA.2 sub‐lineage of the Omicron SARS‐CoV‐2 variant. We performed a retrospective cohort (n = 8850) study of individuals treated with sotrovimab in the community, with the objective of assessing whether there were any differences in risk of hospitalisation of BA.2 cases compared with BA.1. We estimated that the hazard ratio of hospital admission with a length of stay of 2 days or more was 1.17 for BA.2 compared with BA.1 (95%CI 0.74–1.86). These results suggest that the risk of hospital admission was similar between the two sub‐lineages.